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Aim. To describe 7 years of activity of “CROMa” (Coordination of Research on Osteonecrosis of the Jaws) project of
“Sapienza” University of Rome. Materials and Methods. A preventive and therapeutic care pathway was created for patients with
bisphosphonates (BPs) exposure. Demographic, social, behavioural, pharmacological, and clinical variables were registered in
a dedicated database. Results. In the project, 502 patients, 403 females and 99 males, were observed. Bone pathologies were
79% osteometabolic diseases (OMD) and 21% metastatic cancer (CA). Females were 90% in OMD group and 41% in CA. BP
administration was 54% oral, 31% IV, and 11% IM; 89% of BPs were amino-BP and 11% non-amino-BP. Consistently with bone
pathology (OMD/CA), alendronate appears to be prevalent for OMD (40% relative), while zoledronate was indicated in 92% of CA
patients. Out of 502 cases collected, 28 BRONJwere detected: 17 of themwere related to IVBP treatment. Preventive oral assessment
was required for 50% of CA patients and by 4% of OMDpatients.Conclusions.Theproposed care pathway protocols for BP exposed
patients appeared to be useful to meet treatment and preventive needs, in both oncological and osteometabolic diseases patients.
Patients’ and physicians’ prevention awareness can be the starting point of a multilevel prevention system.
1. Introduction
Recently, an osteonecrosis of the jaws (BRONJ) has been
characterized as a main side effect of bisphosphonates (BPs)
therapy [1, 2].
This adverse event, first described by Marx and Stern in
2002 [3], has been characterized as nonhealing exposed bone
in the mandible or maxilla [4–7] or currently defined as an
area of exposed bone in the maxillofacial region that has
persisted for more than 8 weeks in a patient on previous or
current treatment with a bisphosphonate and without history
of radiation therapy to the jaws. Despite this definition, many
cases of nonexposed variant of BRONJ have been reported
[8].
Mucosal swellings, redness, and purulent exudate some-
times with fistula formation are common. Often the patient
complains of pain and discomfort in the mouth, bad taste,
and feeding difficulties [9–12]. BRONJ condition may easily
progress to severe formswith intractable pain, inability to eat,
severe maxillary sinusitis, oroantral fistula, orbital abscess,
extraoral fistula, involvement of the lower margin, and
fracture of the mandible, especially when it affects debilitated
patients [13, 14].
BRONJ has been strongly associated with prolonged use
of intravenous (IV) BP (zoledronate and pamidronate) in
cancer patients, while patients affected by nonneoplastic
diseases and receiving BP with lower dosage or different
routes of administration (oral or intramuscular) seem to
incur more rarely in this adverse event.
Osteonecrosis is often related to the removal of one or
more teeth, to others invasive procedures (i.e., periodontal
surgery, dental implant placement, and endodontic surgery),
or to local risk factors such as periodontal disease [15], but
it can also occur spontaneously, without any apparent dental
disease, treatment, or trauma [11].
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The cumulative incidence recorded over the years by case-
series, case-control, and cohort studies is highly variable,
ranging from 0.8 to 12% [2, 16–24].
For patients exposed to IV BP, the rate of spontaneous
occurrence is between 0.8 and 1.15%, rising to 6.67%–
9.1% when invasive dental procedures are performed. In
noncancer patients, the incidence is between 0.01 and 0.04%,
increasing from 0.09 to 0.34% in case of dentoalveolar
surgery.
Since the first reports focused on BRONJ [1], dental
surgical procedures have frequently been described as trig-
gering factors. It is well known that BRONJ can develop
with dentoalveolar surgery intervention, and tooth extraction
appeared to be the main precipitating risk factor, as it is seen
in up to 65% of reported cases [25].
On the other hand, the presence of odontogenic infec-
tions exposes patients to considerable risk of BRONJ occur-
rence. Particularly, cancer patients exposed to IV BP with
a history of inflammatory dental disease showed a 7-fold
increased risk of developing BRONJ [5]. In fact, many of
the cases reported as “spontaneous,” seemingly lacking a
triggering factor, may have been the result of a not detected
odontogenic focus.
From this point of view, an absolute contraindication
to tooth extraction in BP patients may not be advisable.
Operative dentistry, endodontics, and periodontal noninva-
sive treatments remain the first choice to prevent and resolve
odontogenic local infections, especially in patients currently
or previously treated with BP. Nevertheless “hopeless” non-
restorable teeth should be scheduled for extraction also
in patients already exposed to medication, above all when
their presence prevents the possibility of proper prosthetic
rehabilitation or predisposes to infective conditions.
Furthermore, some inflammatory conditions, such as
localized severe chronic periodontitis or extensive periapical
lesions fromunsuccessful endodontic therapy, not always can
be treated by means of elective dental treatments such as
periodontal therapy or endodontic retreatment, because they
are time-consuming and with uncertain prognosis. Odonto-
genic infections in subjects scheduled for pharmacological
therapy who urgently need to start BP administration for
bone malignancies or severe metabolic bone diseases should
be effectively and timely addressed, and teeth with poor
prognosis or at high risk of infectious complications should
be scheduled for extraction.
The aim of the study is to describe 7 years of activity of
the “CROMa” (Coordination of Research onOsteonecrosis of
the Jaws) project of “Sapienza” University of Rome evaluating
the risk variables of patients with past, present, or planned
BP exposure, treated with periodontics, oral surgery, and
operative dentistry procedures in order to treat or prevent
BRONJ, according also to the recent Italian Ministry of
Health guidelines of April 2014 [26] and SICMF-SIPMO
Italian societies recommendations [27, 28].
2. Materials and Methods
2.1. The CROMa Project. At the Department of Oral and
Maxillofacial Sciences of “Sapienza” University of Rome, in
January 2007, a task force of clinicians and researchers set
up a Coordination of Research on Osteonecrosis of the Jaws
(CROMa). The counselling consists of a multidisciplinary
expert group with thorough knowledge of basic and clinical
bone biology as well as expertise and daily practice in the
fields of preventive dentistry, oral pathology, operative den-
tistry, and oral and maxillofacial surgery.The aim of CROMa
is to prevent or treat established BRONJ and to give relevant
pieces of information and advice both to patients and to BP
prescribing providers. The task force joins several experts
(dentists, oral and maxillofacial surgeons, oral pathologists,
oncologists, and an expert in statistics) in order to provide a
comprehensive patient-centered oral care delivery.
2.2. CROMa Patients Care Pathways. Asymptomatic patients
with no signs of osteonecrosis were addressed to the most
appropriate dental treatment algorithm, consistently with
international protocols, as updated and summarized in
Table 2, according to the recent Italian Ministry of Health
guidelines [26] and SICMF-SIPMO Italian societies recom-
mendations [27, 28].
All patients, with past, current, or planned BPs therapy,
followed 3 possible care pathways.
(A) prevention, (B) surgery, and (C) oral clinics.
Specifically, in the (A) path, patients received professional
oral hygiene and personal oral hygiene instructions; in the (B)
path, they received surgical care: dental extractions and/or
surgical treatment of BRONJ were performed; hopeless teeth,
being potential or actual infection sites, were treated with
extractions. In the (C) path, patients were treated with
operative dentistry and/or endodontics and/or periodontal
treatments, supported also by various types of laser (analgesic
or biostimulating low level laser therapy, surgical lasers for
soft tissues, and ablative lasers for bone treatment) in order
to remove or prevent odontogenic infections and/or to relief
pain [29].
Patients could follow combinations of the care pathways,
according to treatment needs.
All the established BRONJ were treated combining (B)
and (C) pathways, in order to give necessary surgical (tra-
ditional and/or laser guided surgery) and/or biostimulat-
ing (low level laser therapy) and/or medical treatments
(antibiotics, analgesics, antibacterial rinses, integrators of the
immune system, etc.). All patients exposed to BP underwent
clinical procedures according to international guidelines.
2.3. Diagnostic Protocol. Oral health status was assessed
and the presence of jaws pathological or anatomical condi-
tions, acting as potential BRONJ risk factors, or the finding
of suspected osteonecrosis was recorded through physical
examination.
For all patients, to exclude the presence of BRONJ, in
addition to anamnestic notes and clinical features, laboratory
tests and radiographic data, such as orthopantomographs
and full periodontal radiographic exams, were harvested and
examined. No bone turnover biomarkers were used, as they
were judged to be not completely reliable in predicting risk
[30]. In case of suspected BRONJ, to confirm diagnosis,
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Table 1: 2013 SIPMO/SIMCF clinical-radiological staging of BRONJ [28].
Stage 1
Focal BRONJ: in the presence of at least 1 minor clinical sign or of bone thickening on CT limited to
mandibular or maxillary dentoalveolar process∗, with or without other early radiological signs.
Minor clinical signs and symptoms: halitosis, odontogenic abscess, mandibular asymmetry, pain of dental
and/or boned origin, bone exposure, mucosal fistula, postextractive mucosal healing failure, rapid onset tooth
mobility, paresthesia/dysesthesia of the lips, purulent leakage, spontaneous seizure of bone fragments, trismus,
and soft tissues swelling.
Signs on CT: trabecular thickening, bone marrow focal osteosclerosis, with or without thickening of the
alveolar crest, postextractive socket persistence, and periodontal space flare.
(A) Asymptomatic.
(B) Symptomatic (presence of pain and/or suppuration).
Stage 2
Widespread BRONJ: in the presence of at least 1 minor clinical sign or of bone thickening on CT, also extended
to the mandibular or maxillary basal process, with or without late radiological signs.
Minor clinical signs and symptoms: as for Stage 1.
CT signs: widespread osteosclerosis, with or without oroantral and oronasal fistula, thickening of the inferior
alveolar nerve canal, periosteal reaction, bone seizure, and sinusitis.
(A) Asymptomatic.
(B) Symptomatic (presence of pain and/or suppuration).
Stage 3
Complicated BRONJ: as in Stage 2, in the presence of 1 or more of the following signs.
Minor clinical signs: extraoral fistula, leakage of fluid from the nose, and preternatural mobility of the jaw with
or without occlusion preservation.
CT signs:mucocutaneous fistula, pathologic fracture, osteolysis extended to maxillary sinus, and cheekbone
and/or hard palate osteosclerosis.
∗Dentoalveolar bone anatomical structure that constitutes the skeletal support for the teeth. By definition, the dentoalveolar process ends in craniocaudal
direction immediately below the root of the teeth.
computed tomography (CT) scans imaging and further lab-
oratory tests were requested, as needed. Lesions were staged
in the beginning according to AAOMS Position Paper 2007
[4], modified in 2009 [5]. Later, we used SIPMO/SICMF
recommendations 2011 [27] and 2013 [28] (Table 1). Every
new classificationwe adopted through these 7 years of activity
has been followed by a review of our BRONJ patient collected
data (radiographies, clinical chart, pictures, etc.) to make
every case up to date.
2.4. Data Collection. A unified clinical chart was developed
in order to collect all necessary data in a digital online
database.
Age, gender, presence of systemic diseases, use of any
drugs, and the main systemic and local risk factors were
registered. Patients were asked for a comprehensive history
concerning the use, dose, frequency, and duration of therapy
with BP.
The parameters to define a patient at higher or lower risk
to develop BRONJ were identified in the limit of 3 years for
oral and IM BP therapy and of 8 infusions for IV BPs [24].
Only patients with past, present, or planned BP exposure
were included in the CROMa project, with or without
established BRONJ.
Patients have been catalogued following a chronological
sequence into a Microsoft Access database, editable and
searchable online by all the main components of the CROMa
project.
2.5. Data Analysis. The collected samples (January 2007–
March 2014) of patients were examined according to
gender (male/female), age, bone disease (osteometabolic
(OMD)/oncological (CA)), type of drug (amino-BP/non-
amino-BP), BP active ingredient (alendronate/zoledronate,
etc.), the route of administration (oral (OS)/intramuscular
(IM)/intravenous (IV), or their combination), administration
time (months of therapy, then divided into 2 categories for
OS/IM (< or >3 years) and 2 categories for IV (< or >8
infusions)), and the timing (current, past, or planned BP
therapy).
In addition, systemic and local risk factors for BRONJ and
BRONJ presence and staging were also analyzed.
Data were coded and imputed into an Excel 2013 spread-
sheet (Microsoft Inc., Redmond, WA, USA) and checked to
verify the accuracy. Statistical analysis was performed using
Stata 13.0 (San Diego, CA, USA) for the Macintosh operating
system. Initially, univariate analyses were performed on the
clinical condition parameters and potential risk indicators to
describe the variables and distributions. Then a descriptive
statistical analysis was performed. To avoid the attenuating
effect of unequal variability among groups on the value
of 𝑡, a square root transformation was performed when
the response variable was a count. The association between
BRONJ and background factors was tested using the 𝜒2 test.
A stepwise logistic regression model was built using the
presence of at least one BRONJ lesion as the dependent
variable. Gender has been identified as amodifier effect in the
statistical analysis. Therefore, two different logistic models
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Table 2: Oral procedures in patients with current/past or planned BP therapy [28].
Malignancies Osteometabolic disorders




>3 years of NBP






Recommended Recommended Recommended Recommended
Simple extraction1 Surgical extraction2 Simple extraction Surgicalextraction2
To wait until mucosal
healing before starting








surgery Not recommended Not recommended Possible Possible
4
Implantology Not recommended Not recommended Possible3 Possible3,4
Periodontal surgery
Therapeutic
Recommended2,5 Recommended2,5 Recommended Recommended2





(4–6 weeks) from extraction day untilmucosal healing
(4–6 weeks)
Elective Not recommended Not recommended Possible Possible




(every 4 months) (every 4–6months)
Conservative Recommended Recommended Recommended Recommended
Endodontics Recommended Recommended Recommended Recommended
Orthodontics Possible Possible (recommendedlow orthodontic forces) Possible Possible
Fixed prosthesis Possible Possible6 Possible Possible6
Removable prosthesis
Possible Possible Possible Possible
Avoid injuries and











1If BP therapy cannot be delayed, choose surgical extraction; 2usemucoperiosteal flap for primary closure of the surgical site; 3informed consent for not defined
long-term BRONJ risk; 4informed consent for not defined short-term BRONJ risk; 5only for the treatment of significant infectious-inflammatory processes,
not otherwise controllable using noninvasive methods; 6respect of the biological width (control of cervical closure-possible supragingival closure).
stratified by gender were run following robust statistics
(24. Wilcox RR. Introduction to Robust Estimation and
Hypothesis Testing (Third Edition) Elsevier Inc. 2013). Unless
stated otherwise, the criterion for statistical significance was
set at 𝛼 = .05.
3. Results
From January 2007 toMarch 2014, 502 patients (Table 3) were
included in the CROMa project, including 403 females and
99 males aged between 8 and 90 years. Bone diseases were
79% of osteometabolic type (OMD, 398 cases, of which 310
were for osteoporosis (78% rel. | 62% tot.), 54 for osteogenesis
imperfecta (13% rel. | 11% tot.), and 13 for osteopenia (3%
rel. | 2,5% tot.)) and 21% of oncological type (CA, 104 cases,
including 34 for bone metastases from prostate cancer (33%
rel. | 7% tot.), 28 from mammary cancer (27% rel. | 5% tot.),
and 14 from multiple myeloma (13% rel. | 3% tot.)).
The OMD concerned 90% of women and 10% of men,
while CA patients were 41% females and 59% males. The
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Prostate cancer bone metastasis 34
Mammary cancer bone metastasis 28
Multiple myeloma 14
Renal cancer bone metastasis 11
Pulmonary cancer bone metastasis 9
Other 8
BP administration
BP therapy 58 (11%)





Patients with no BRONJ 474 (94,42%)
Patients with BRONJ 28 (5,58%)
BRONJ from oral BP 11
BRONJ from IV BP 17
routes of BP administration were mostly oral (54%), followed
then by IV therapies (31%), IM (11%), and an association of
these in 3% of cases.
The active principles administered have seen in the whole
group a prevalence of amino-BP drugs (89%), including
alendronate (33% tot.), zoledronic acid (21% tot.), risedronate
(17% tot.), neridronate (12% tot.), and ibandronate (6% tot.),
compared to non-amino-BP administration (11%) repre-
sented only by clodronate.
The distribution according to bone diseases (OMD/CA)
has seen alendronate as a drug of choice for OMD (40%
rel.) followed by risedronate (21% rel.), while, in the other
category, zoledronic acid was indicated in 92% of patients
with metastatic bone cancer.
An analysis of the BP planned therapies group highlights
that, out of 155 cases of IV therapy, 78 patients (50%) were
referred for oral health assessment before starting the drug
administration: the trend is completely different for the oral
therapies (4%, 12 cases out of 270) and IM therapies (3%, 2
cases out of 60).
Out of 502 patients (Table 4), 28 differently staged BRONJ
were intercepted at first examination (3 at Stage 0, 8 at Stage 1,
12 at Stage 2, and 5 at Stage 3), 17 in the CA group (16,4%), and
11 in theOMDgroup (2,2%).The outcome is overlappingwith
the therapy regimen variable (17 from IV BP administration
(11% of all IV) and 11 from oral BP drugs (4,1% of all OS)). No
BRONJ in our study has been related to exposition to non-
amino-BP. From the logistic regression model (Table 5), we
can observe how BRONJ risk in male patients is significantly
connected principally to therapy intervals, while in women
the risk is influenced also by behavioral habits, oncologic type
of bone disease, and therapy regimen.
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(𝑛%)∗ OR (95% CI)
Osteometabolic disease 11 (2,2%) 387 (97,8%) —
Metastatic cancer 17 (16,4%) 87 (83,6%) 0.20 (0.11–0.33)
𝜒
2 for trend 28.82, 𝑃 < .01
Therapy intervals
No therapy 1 (1%) 92 (99%) —
<3 years 7 (3,9%) 172 (96,1%) 0.02 (0.01–0.07)
>3 years 4 (2,7%) 146 (97,3%) 0.03 (0.01–0.07)
IV < 8 infusions 2 (11,8%) 15 (88,2%) 0.13 (0.03–0.58)
IV > 8 infusions 14 (22,2%) 49 (77,8%) 0.29 (0.16–0.52)
𝜒
2 for trend 41.23, 𝑃 < .01
Therapy regimen
Association between methods 0 (0%) 17 (100%) —
IV 17 (11%) 138 (89%) 0.12 (0.07–0.20)
IM 0 (0%) 60 (100%)
OS 11 (4,1%) 259 (95,9%) 0.05 (0.02–0.07)
𝜒
2 for trend 4.31, 𝑃 = .04
∗The percentage (𝑛 %) is not absolute but is relative to the specific field.
Table 5: Logistic regression model (forward stepwise procedure) for BRONJ presence, stratified for gender.
(a) Male
Variable OR Robust (SE) 𝑃 95% CI
Behavioral habits .92 .15 0.62 1.07–1.39
Therapy intervals 3.14 1.01 <.01 1.68–5.89
Number of observations= 61; log likelihood= −13.27; 𝜒2
(2)
= 24.50; 𝑃 value < .01.
(b) Female
Variable OR Robust (SE) 𝑃 95% CI
Behavioral habits 1.22 .08 <.01 1.07–1.39
Oncology bone disease 17.90 14.03 <.01 3.85–83.25
Therapy regimen 2.85 1.41 .03 1.08–7.50
Therapy intervals 2.37 .73 <.01 1.29–4.32
Number of observations= 403; log likelihood= −60.03; 𝜒2
(4)
= 33.10; 𝑃 value < .01.
Between 28 BRONJ patients, 13 were being treated with
chemotherapy, 8 were receiving prolonged therapy with
glucocorticoids, 4 were smokers, and 2 had diabetes.
In addition, clinical and radiological examination under-
lined that 6 of themhad odontogenic infections, and the same
percentage had poor oral hygiene and periodontal disease.
4. Discussion
The CROMa project was created with the primary intent to
be a benchmark for dental patients exposed to the BP drugs
or about to take them. Meticulous collection of personal,
epidemiological, and clinical data has provided a fairly
complete overview of the population exposed to the drug
who presented to our department. Interestingly, 86% of the
patients with nonintravenous BP therapy were addressed to
the Department of Dentistry for a routine dental visit or
for emergency dental treatments; only 4% was asked for an
oral health assessment before BP administration. Overall,
these patients showed poor awareness of the clinical concerns
associated with BP intake, and poor information had been
provided by the prescribing physician about the possibility of
BRONJ occurrence after dentoalveolar surgical procedures.
On the contrary, patients with intravenous BP therapy
for bone malignancies or dysplastic bone diseases showed a
greater awareness and understanding of the issue and were
referred to CROMa by the specialist who treated them for the
underlying disease (50%were referred before IV BP therapy).
This disparity is probably due to the statistics which
define a higher risk only or above all for the IV therapies.
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Nevertheless, as shown by our data, the BRONJ occurrence
subsequently to oral BP administration is possible, also con-
sidering the much higher number of patients exposed to oral
BP administration than to the IV one. In 2005, alendronate
was the 15th most prescribed drug with approximately 18
million prescriptions and risedronate was the 37th with
almost 10 million prescriptions [31]. Furthermore, our study
shows how BPs are prescribed even in case of osteopenia
(2,5% tot.) rather than prescribing other drugs with fewer
possible side effects.
Overall, data analysis shows that themost at-risk situation
is in the metastatic bone cancer group, treated with IV
administration of NBP, for a long therapy interval (more than
8 infusions), with females being much more represented in
the OMD group, due to postmenopausal osteoporosis.
At the state of knowledge, a specific evidence-based
treatment protocol for BRONJ has not been established.
At present, literature provides clinician with only a few
indications of possible treatment algorithms through case
reports and case series. In 2013, a new clinical-radiological
staging was defined, which considers also the radiographic
extension of BRONJ and the further classification of Stage 1
and Stage 2 in asymptomatic (1A) and symptomatic (1B) [28].
However, as all current treatments appear to be subopti-
mal and no consensus has been reached on completely effec-
tive and predictable approach once BRONJ has developed,
the best chances are in prevention.
Themost important goal of CROMa project is specifically
prevention. Currently, preventive approach is not yet com-
mon amongprescribers of oral BP. Prevention should bemore
strongly promoted by sharing knowledge in the involved
medical community and establishing a fruitful cooperation
with the specialist prescriber of the BP drug, working as a
team on behalf of patient.
Moreover, in our study, all the patients with BRONJ
who have been treated with surgery following our protocols
and algorithms have reported a relief of the symptoms and
an improvement of their quality of life. No recurrence of
BRONJ has been reported during the follow-ups after 4, 8,
and 12 months from surgery. Furthermore, no evidence of
BRONJ has been found in any OMD or CA patient during
the following planned scaling/root planning treatments.
5. Conclusions
Although BRONJ is a relatively rare side effect of BP therapy,
it is still an important issue for the medical community due
to the severity of the condition and the lack of a thorough
understanding of the pathophysiology and predisposing risk
factors. An accurate delineation of the pathogenic mecha-
nisms at the cellular and biochemical levels, as well as clinical
and laboratory markers for prediction of BRONJ susceptibil-
ity in the single subject, is still lacking. From a clinical point
of view, no evidence-based recommendations exist about the
dental treatments that can be performed without risk or with
appropriate risk-benefit ratio. Furthermore, the protocols of
treatment to manage overt disease appear to be suboptimal.
The preventive and therapeutic protocols of BRONJ
currently proposed appeared to be useful.
Our patients, referred by other specialists or simply
intercepted during the medical history collection in the first
observation unit, have been treated in order to meet their
immediate needs and then to minimize BP-related risks
for oral health, following the best practice preventive and
treatment protocols.
Focusing on prevention, it is important that the involved
medical community share knowledge and that the physicians
take a conscious attitude so as to provide patients with the
highest quality of oral health care, before starting BP therapy,
in order to improve the care and oral health-related quality
of life of patients, in both oncological and osteometabolic
diseases. Prevention awareness, aided also by the networking
use of an online database, can be the starting point of a
multilevel prevention system.
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